for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Neuralstem, Inc.

CUR.OQ

Latest Trade

1.25USD

Change

-0.05(-3.85%)

Volume

8,360

Today's Range

1.25

 - 

1.34

52 Week Range

1.10

 - 

24.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.30
Open
1.30
Volume
8,360
3M AVG Volume
2.69
Today's High
1.34
Today's Low
1.25
52 Week High
24.00
52 Week Low
1.10
Shares Out (MIL)
2.64
Market Cap (MIL)
3.43
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Neuralstem Q2 Loss Per Share $1.45

Intracoastal Capital LLC Reports 9.99% Passive Stake In Neuralstem Inc As Of July 30

Neuralstem Announces Pricing Of $7.5 Mln Underwritten Public Offering

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Neuralstem, Inc.

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company's technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company's NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

Industry

Biotechnology & Drugs

Contact Info

20271 Goldenrod Ln Ste 2024

+1.301.3664841

https://www.neuralstem.com/

Executive Leadership

Kenneth C. Carter

Executive Chairman of the Board

Cristina Csimma

Director

Mary Ann Gray

Director

David J. Mazzo

Director

Binxian Wei

Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
222.86
Price To Book (MRQ)
0.67
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-122.76
Return on Equity (TTM)
-105.08

Latest News

Latest News

BRIEF-Neuralstem Announces First Surgery Completed In Cervical Cohort Of Phase 1 Clinical Trial In Patients With Chronic Spinal Cord Injury

* NEURALSTEM ANNOUNCES FIRST SURGERY COMPLETED IN CERVICAL COHORT OF PHASE 1 CLINICAL TRIAL IN PATIENTS WITH CHRONIC SPINAL CORD INJURY Source text for Eikon: Further company coverage:

BRIEF-Neuralstem Q3 loss per share $0.01

* Neuralstem reports third quarter 2017 fiscal results and provides clinical and business update

BRIEF-Neuralstem Inc appoints two members to its board

* Neuralstem announces the appointment of two new members to the board of directors

BRIEF-Neuralstem Inc gets two additional U.S. patents

* Neuralstem Inc - been awarded two additional patents by United States Patent and Trademark Office Source text for Eikon: Further company coverage:

BRIEF-Neuralstem reports Q2 loss per share $0.39

* Neuralstem reports second quarter 2017 fiscal results and provides clinical and business update

BRIEF-‍CVI investments reports a 8.3 pct passive stake in Neuralstem

* CVI Investments reports a 8.3 percent passive stake in Neuralstem Inc as of July 27, 2017 - SEC filing Source text: (http://bit.ly/2vbUBwE) Further company coverage:

BRIEF-Neuralstem awarded grant by NIH to continue preclinical research into treatment for diabetic neuropathy

* Neuralstem awarded $~1mm grant by NIH to continue preclinical research into the potential of nsi-189 for treatment of diabetic neuropathy Source text for Eikon: Further company coverage:

BRIEF-Neuralstem announces top-line phase 2 data of nsi-189 for major depressive disorder

* Neuralstem announces top-line phase 2 data of nsi-189 for major depressive disorder

BRIEF-Neuralstem files for mixed shelf of up to $100 mln

* Neuralstem Inc files for mixed shelf of up to $100 million -sec filing Source text - http://bit.ly/2s17fgR Further company coverage:

BRIEF-Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder

* Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder Source text for Eikon: Further company coverage:

BRIEF-Neuralstem reports Q1 loss per share $0.68

* Neuralstem reports first quarter 2017 fiscal results provides clinical and business update

BRIEF-Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury

* Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury

BRIEF-Neuralstem reports year end 2016 fiscal results

* Neuralstem reports year end 2016 fiscal results and business update

BRIEF-Neuralstem to continue as going concern is dependent on generating cash from the sale of its common stock

* Neuralstem-Co's ability to continue as going concern is dependent on generating cash from the sale of its common stock and/or obtaining debt financing

BRIEF-Tianjin Pharmaceuticals Group International Holdings reports 19.99 pct stake in Neuralstem - SEC Filing

* Tianjin Pharmaceuticals Group International Holdings Co., Ltd reports 19.99 percent stake in Neuralstem Inc - SEC filing Source - (http://bit.ly/2l5LaeR) Further company coverage:

BRIEF-Neuralstem announces a 1-for-13 reverse stock split

* Reverse stock split will become effective on Friday, January 6, 2017 Source text for Eikon: Further company coverage:

BRIEF-Neuralstem reports third quarter 2016 results

* Qtrly loss per share $0.05 Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up